SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Edgar Ben-Josef,Katherine A. Guthrie,Anthony B. El-Khoueiry,Christopher L. Corless,Mark M. Zalupski,Andrew M. Lowy,Charles R. Thomas,Steven Robert Alberts,Laura A. Dawson,Kenneth C. Micetich,Melanie B. Thomas,Abby B. Siegel,Charles D. Blanke

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

2015

Edgar Ben-Josef
Katherine A. Guthrie
Anthony B. El-Khoueiry
Christopher L. Corless
Mark M. Zalupski
Andrew M. Lowy
Charles R. Thomas
Steven Robert Alberts
Laura A. Dawson
Kenneth C. Micetich
Melanie B. Thomas
Abby B. Siegel
Charles D. Blanke

Purpose The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown. S0809 was designed to estimate 2-year survival (overall and after R0 or R1 resection), pattern of relapse, and toxicity in patients treated with this adjuvant regimen.

Keywords:

Capecitabine
Carcinoma
Adjuvant
Gallbladder
Regimen
Gemcitabine
Radiation therapy
Internal medicine
Oncology
Medicine
Extrahepatic Cholangiocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

189

Citations